202 Results for "

binding properties

" in MedChemExpress (MCE) Product Catalog:
Products (202)

202 Results for "binding properties" in MCE Product Catalog:

Cat. No.: HY-P5284
CAS No.: 1613231-49-4
Target:  

Inhibitory Antibodies

Research Areas:  

Others

RALA peptide is a cationic amphiphilic delivery agent targeting cell membranes, which forms nanoparticles through electrostatic interactions with anionic drugs. RALA peptide has pH-responsive binding properties, which can enhance the α-helical conformation in an acidic environment and destroy the endosomal membrane, promote the release of drugs into the cytoplasm, and exert efficient intracellular delivery activity. RALA peptide can be used in cancer research (enhancing the activity of bisphosphonates against prostate cancer and breast cancer cells) and bone tissue engineering (promoting osteoblast collagen deposition and extracellular matrix mineralization) .
loading...
    loading...
Cat. No.: HY-164725
CAS No.: 3023869-94-2
Research Areas:  

Cancer

FAPI-mFS is a selective fibroblast activation protein (FAP) inhibitor with an IC50 of 0.0014 μM against human FAP. Through its covalent binding property with FAP, FAPI-mFS enhances its uptake and retention time in cancer cells. When radiolabeled with 68Ga, FAPI-mFS serves as a PET/CT imaging agent with superior tumor-to-background tissue contrast and lesion detection capability. When radiolabeled with 177Lu or 225Ac, FAPI-mFS induces tumor regression and inhibition in preclinical models. FAPI-mFS can be used in studies related to cancer and radionuclide-conjugated drugs (RDC) .
loading...
    loading...
Cat. No.: HY-L941
4,236 compounds

Orthosteric sites are highly conserved, leading to poor subtype selectivity, off-target toxicity and drug resistance in traditional drugs. By contrast, allosteric sites show low conservation, high hydrophobicity, weak polarity, confined geometry and dynamic cryptic properties, granting modulators high selectivity, functional tunability and safety. Thus, allosteric therapy has become a major focus in drug discovery.

MCE curated nearly 1,000 clinical-stage allosteric modulators, analyzed PDB complex structures to identify key pharmacophores and privileged scaffolds, then designed and filtered compounds using rational “scaffold derivation + physicochemical screening” with strict property criteria. The resulting compounds show high rigidity and shape complementarity to shallow, dynamic, hydrophobic allosteric pockets.

This library comprises 4,315 diverse, lead-like compounds ideal for allosteric drug discovery and target screening, covering kinases, GPCRs and more. All are analogs of clinical-stage molecules with similarity > 0.6, combining high druggability and allosteric binding potential to support efficient early-stage R&D.

Cat. No.: HY-145962
CAS No.: 2621927-57-7
Target:  

Ras

Research Areas:  

Cancer

MRTX-EX185 is a potent KRAS (G12D) inhibitor with an IC50 of 90 nM. MRTX-EX185 can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 exhibits broad-spectrum binding properties with IC50s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 can be used to study various RAS-driven tumors (such as pancreatic cancer) .
loading...
    loading...
Cat. No.: HY-159921
CAS No.: 3033099-32-7
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

Tubulin Polymerization-IN-1 prodrug (Compound 2b) is a palladium (Pd)-mediated tubulin polymerization inhibitor prodrug. Developed based on colchicine binding site inhibitors (CBSIs), it reduces toxicity and enhances targeted release properties. Compared to the parent compound, Tubulin Polymerization-IN-1 prodrug exhibited 68.3-fold lower cytotoxicity, which can be restored in situ in the presence of Pd resin. Mechanistic studies showed that its anticancer activity is consistent with CBSIs. In vivo, Tubulin Polymerization-IN-1 prodrug significantly inhibited tumor growth (63.2%) when activated by Pd resin. It holds promise for research in the field of anticancer therapy .
loading...
    loading...
Cat. No.: HY-165460
CAS No.: 414858-51-8
AM-112 is a β-lactamase (β-lactamase) inhibitor and antibacterial agent, with IC50 values ranging from 0.0002 μg/mL to 0.67 μg/mL against class A, C, and D β-lactamase. By inhibiting PBP2, the penicillin-binding protein of E. coli, and protecting Ceftazidime (HY-B0593) from enzymatic hydrolysis, AM-112 significantly enhances the antibacterial efficacy of Ceftazidime against Gram-negative bacteria, enterococci, and staphylococci. AM-112 exhibits favorable pharmacokinetic properties and acid-base stability. AM-112 can be used for the research of bacterial infections .
loading...
    loading...
Cat. No.: HY-B1390A
CAS No.: 128-44-9
Research Areas:  

Infection

Saccharin sodium is an orally active, non-caloric artificial sweetener (NAS). Saccharin sodium has bacteriostatic and microbiome-modulating properties. Saccharin binds to and signals via specific taste receptors, not only in the oral cavity but also alongside the gastrointestinal tract. Saccharin has been reported to bind the human and rodent heteromeric guanine nucleotide-binding protein (G protein) coupled sweet taste receptors T1R2/T2R3 as well as the human bitter taste receptor T2R43 and T2R44. Saccharin can inhibit bacterial growth in vitro .
loading...
    loading...
Cat. No.: HY-G0002
CAS No.: 186204-33-1
Lurasidone metabolite 14326 is a minor active metabolite of Lurasidone (HY-B0032A) generated via metabolism by CYP3A4. Lurasidone metabolite 14326 shares similar receptor-binding properties with Lurasidone, acting as an antagonist of the dopamine D2 receptor (dopamine D2 receptor), an antagonist of the serotonin 5-HT2A and 5-HT7 receptors (5-HT2A and 5-HT7 receptor), and a partial agonist of the serotonin 5-HT1A receptor. Lurasidone metabolite 14326 can be used in the research of schizophrenia and bipolar depression .
loading...
    loading...
Cat. No.: HY-G0002A
Lurasidone metabolite 14326 hydrochloride is a minor active metabolite of Lurasidone (HY-B0032A) generated via metabolism by CYP3A4. Lurasidone metabolite 14326 hydrochloride shares similar receptor-binding properties with Lurasidone, acting as an antagonist of the dopamine D2 receptor (dopamine D2 receptor), an antagonist of the serotonin 5-HT2A and 5-HT7 receptors (5-HT2A and 5-HT7 receptor), and a partial agonist of the serotonin 5-HT1A receptor. Lurasidone metabolite 14326 hydrochloride can be used in the research of schizophrenia and bipolar depression .
loading...
    loading...
Cat. No.: HY-P992365

Target:  

CCR

Research Areas:  

Cancer

HFB101110 is a human-derived inhibitor and Treg depleter that specifically targets CCR8. It does not bind to the homologous CCR4 receptor and is mainly used in research on solid tumors, renal cell carcinoma and colorectal cancer. HFB101110 blocks hCCL1 binding by interacting with the N-terminal extracellular domain of hCCR8, thereby inhibiting hCCL1-induced calcium influx, chemotaxis and downstream signaling pathways. Meanwhile, HFB101110 can mediate ADCC effects to specifically deplete CCR8-positive cells, including intratumoral Tregs. HFB101110 exhibits favorable anti-tumor activity and pharmacokinetic properties .
loading...
    loading...
Cat. No.: HY-L255
72 compounds

Dipeptide compounds have attracted extensive attention in drug discovery and life science research due to their simple structures, ease of modification, and favorable biocompatibility. As small peptides composed of two amino acids, dipeptides exhibit diverse biological activities, including anti-inflammatory, antioxidant, antimicrobial, anticancer, and immunomodulatory effects, showing significant application potential in metabolic disorders, neurological diseases, and cancer research. Compared with traditional small molecules, dipeptide compounds possess favorable target-binding properties and high structural plasticity, making them valuable tools for drug screening and mechanism studies.

The MCE Dipeptide Compound Library contains 72 dipeptide compounds and can be applied to peptide drug discovery and development.

Cat. No.: HY-182354
CAS No.: 861877-12-5
Research Areas:  

Cancer

VEGFR2-IN-84 is an orally active, multi-targeted tyrosine kinase inhibitor based on a naphthalene ring scaffold. VEGFR2-IN-84 inhibits VEGFR2 with sub-nanomolar affinity and broadly targets kinases including Kit, FGFR, PDGFR, and Ret. By competitively binding to the ATP-binding pocket, VEGFR2-IN-84 blocks the phosphorylation of VEGFR2 and its downstream AKT/ERK signaling pathway, thereby significantly inhibiting endothelial cell proliferation, migration, and tumor angiogenesis. VEGFR2-IN-84 exhibits broad-spectrum antiproliferative activity against various solid tumors such as liver cancer, lung cancer, and renal cancer, shows weak toxicity to normal cells, and has superior potency to Lenvatinib (HY-10981). VEGFR2-IN-84 possesses favorable pharmacokinetic properties and high safety (LD50>2000 mg/kg), and can be used in related studies of various malignant tumors .
loading...
    loading...
Cat. No.: HY-116282W
CAS No.: 9011-18-1
Synonyms: DSS (MW 6500-10000); DXS (MW 6500-10000)
Dextran sulfate sodium salt (DSS) (MW 6500-10000) is a polymer of dehydrated glucose with a molecular weight of approximately 5000. Dextran sulfate sodium salt with different molecular weights exhibits different biological activities. Dextran sulfate sodium salt (MW 6500-10000) has antiviral activity against HIV-1 and HIV-2. Dextran sulfate sodium salt (MW 6500-10000) blocks the binding of virions to CD4 T lymphocytes and inhibits syncytia formation. Dextran sulfate sodium salt (MW 6500-10000) also prevents experimental urolithiasis due to its cytoprotective actions. Moreover, because of its biocompatible and highly charged properties, Dextran sulfate sodium salt (MW 6500-10000) is a suitable choice for pharmaceutical systems .
loading...
    loading...
Cat. No.: HY-125447
CAS No.: 145941-07-7
Artemisinin B is an orally active sesquiterpene natural product with anti-neuroinflammatory activity, which can be found in Artemisia annua Linn.. Artemisinin B suppresses the TLR4-MyD88-NF-κB signaling pathway by reducing the protein levels of TLR4 and MyD88, as well as inhibiting the mRNA expression of NF-κB p65. Artemisinin B reduces the expression of pro-inflammatory cytokines and attenuates synaptic loss, which can be used for the research of cognitive and behavioral impairments in Alzheimer's disease. Artemisinin B shows no cytotoxicity against human cardiomyocytes and exhibits very weak binding to hERG, suggesting its potential for cardioprotective property research .
loading...
    loading...
Cat. No.: HY-133031A
CAS No.: 474084-56-5
Research Areas:  

Others

CSV0C018875 hydrochloride is a G9a (EHMT2) inhibitor that inhibits G9a activity. CSV0C018875 can effectively inhibit G9a activity in both enzyme and cell-based assays, and its toxicity is much lower than that of the known G9a inhibitor BIX-01294. CSV0C018875 binds tightly to the active site cavity of G9a, thereby improving the binding firmness and prolonging the residence time of the compound, further enhancing the inhibitory effect of G9a. CSV0C018875 has the potential to improve its ADME (absorption, distribution, metabolism and excretion) and pharmacodynamic properties through further optimization .
loading...
    loading...
Cat. No.: HY-145962A
CAS No.: 2988148-70-3
Purity:  97.32%
Target:  

Ras

Research Areas:  

Cancer

MRTX-EX185 formic is a potent KRAS (G12D) inhibitor with an IC50 of 90 nM. MRTX-EX185 formic can binds both GDP-loaded and active GNP states of KRAS and KRAS (G12D). MRTX-EX185 formic exhibits broad-spectrum binding properties with IC50s of 110, 290, 130 and 240 nM for KRAS WT, KRAS (G12C), KRAS (Q61H), KRAS (G13D). MRTX-EX185 formic also binds GDP-loaded HRAS. MRTX-EX185 formic can be used to study various RAS-driven tumors (such as pancreatic cancer) .
loading...
    loading...
Cat. No.: HY-B0696
CAS No.: 115103-54-3
Synonyms: NO050328; NO328; TGB
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
loading...
    loading...
Cat. No.: HY-B0696A
CAS No.: 145821-59-6
Synonyms: NO050328 hydrochloride; NO328 hydrochloride; TGB hydrochloride
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
loading...
    loading...
Cat. No.: HY-B0696B
CAS No.: 145821-57-4
Synonyms: NO050328 hydrochloride hydrate; NO328 hydrochloride hydrate; TGB hydrochloride hydrate
Target:  

GABA Receptor

Research Areas:  

Neurological Disease

Tiagabine (NO050328; NO328; TGB) hydrochloride hydrate is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride hydrate exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride hydrate is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
loading...
    loading...
Cat. No.: HY-D3125
Target:  

Fluorescent Dye

Research Areas:  

Others

NtHzBtd is a fluorescent probe for detecting Fe 3+. NtHzBtd is applicable to the selective fluorescent detection of Fe 3+ ions and live cell imaging studies. NtHzBtd can selectively coordinate with Fe 3+ to form a 1:1 complex, triggering chelation enhanced quenching (CHEQ) and intramolecular charge transfer (ICT) processes, which result in fluorescence turn-off, thereby enabling sensitive detection of Fe 3+ and live cell fluorescence imaging. After binding to Fe 3+, NtHzBtd reduces fluorescence intensity, exhibits a rapid response property, with a limit of detection of 0.036 μM and a response time of approximately 55 s. The detection wavelengths are Ex/Em = 334/401 nm (solution system) .
loading...
    loading...